[1]Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies[J]. Nature.
1997,388(6645):839-40.
[2]Gandhi S, Wood NW. Molecular pathogenesis of Parkinson's disease[J]. Human molecular genetics.2005,14(18):2749-55.
[3]Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinson's disease[J]. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry. 2002,8(3):192-7.
[4]Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc. 2007;2(1):141–51.
[5]Stoker TB1, Greenland JC1, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec. Chapter 5.
[6]http://omim.org/entry/163890?search=SNCA&highlight=snca
[7]Giasson BI, Duda JE, Quinn SM, et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34(4):521-33